Go Pro
→ The trade I’ve been waiting for since 2011 (From Traders Agency) (Ad)tc pixel
NASDAQ:PEPG

PepGen Q1 2026 Earnings Report

PepGen logo
$3.11 -0.07 (-2.20%)
As of 09/4/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

PepGen EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.31
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

PepGen Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PepGen Announcement Details

Quarter
Q1 2026
Date
5/12/2026
Time
Before Market Opens
Conference Call Date
Tuesday, May 12, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

PepGen's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

PepGen's Q1 2026 Press ReleasePress Release
(8-K)
PepGen's Q1 2026 Quarterly reportQuarterly report
(10-Q)

PepGen Earnings Headlines

DSMB approves dose escalation in PepGen’s FREEDOM2-DM1 study
August 7, 2026  |  msn.comhttps://www.msn.com/en-us/health/medical/dsmb-approves-dose-escalation-in-pepgen-s-freedom2-dm1-study/ar-AA29C56B
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
August 6, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260806689062/en/PepGen-to-Advance-PGN-EDODM1-Into-Highest-Dose-Cohort-in-Phase-2-FREEDOM2-DM1-Study-Following-DSMB-Review/
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
 |  Chaikin Analytics (Ad)
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
August 6, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260806833210/en/pepgen-reports-second-quarter-2026-financial-results-and-recent-corporate-highlights/
PepGen Inc. (PEPG) Stock Price, News, Quote & History - Yahoo Finance
July 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/PEPG/
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
July 8, 2026  |  stockhouse.comhttps://stockhouse.com/news/press-releases/2023/10/12/pepgen-inc-announces-fda-has-lifted-the-clinical-hold-on-its-investigational-new
See More PepGen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PepGen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PepGen and other key companies, straight to your email.

About PepGen

PepGen (NASDAQ:PEPG) (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome). These in vivo gene editing candidates are engineered to restore enzyme activity in affected tissues, potentially reducing the burden of repeated interventions. Beyond lysosomal storage disorders, PepGen is advancing earlier-stage research in inherited cardiovascular and metabolic conditions leveraging the same platform.

Founded in 2020 by a cohort of genome engineering scientists, PepGen has assembled an interdisciplinary team with expertise in translational research, clinical development and regulatory strategy. The company’s research operations are based in San Diego, where it maintains research laboratories and manufacturing collaborations. PepGen also partners with academic institutions and clinical centers across the United States to support preclinical studies and future clinical trial sites.

Under the leadership of Chief Executive Officer David Becker, who previously held senior roles at multiple biotechnology firms, PepGen is preparing its pipeline for regulatory interactions and human trials. The company has initiated strategic alliances to extend its capabilities in vector production and to explore commercialization pathways in North America and Europe.

View PepGen Profile
Earnings Tools